Background Anti-programmed death (PD)-1 therapy has recently been used in recurrent or
metastatic (R/M) nasopharyngeal carcinoma (NPC). The long-term survival and its …

BACKGROUND Chemotherapy, target therapy, and immunotherapy are increasingly being
used in the systematic treatment of nasopharyngeal carcinoma (NPC), during which the …

Objectives This study aims to compare two induction chemotherapy regimens, TPF and GP,
for patients with locally advanced nasopharyngeal carcinoma (NPC). Materials and methods …

Nephrotoxicity is an important limitation to the clinical use of many drugs and contrast media.
Drug nephrotoxicity occurs in acute, subacute and chronic manifestations ranging from …

Nasopharyngeal carcinoma (NPC) is endemic in Southern China, Taiwan, Malaysia,
Singapore, North Africa and Alaska. About 30% of NPC patients develop recurrence or …

Antibodies targeting the programmed cell death protein-1 (PD-1) molecule have been
reported to hold promising antitumor activities in patients with nasopharyngeal carcinoma …

Combination chemotherapy, such as doxorubicin (Dox) plus cisplatin, based on co-
assembling nanoparticles plays increasingly important role in the clinical treatment of …

Objectives There is currently no effective salvage therapeutic modality that improves the
survival outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma …

Background The strategy of dual blockade of TGF-β and PD-L1 pathways has not been
previously tested in platinum-refractory recurrent or metastatic nasopharyngeal cancer (R/M …

Purpose Nasopharyngeal carcinoma (NPC) is ranked the top otorhinolaryngology malignant
tumors in the world. However, the general prognosis of recurrent and metastatic (R/M) …